SciELO - Scientific Electronic Library Online

vol.107 issue2Impact of a respiratory disease prevention program in high-risk preterm infants: a prospective, multicentric studyGrowth references for weight and height for argentinian girls and boys from birth to maturity: Incorporation of data from the World Health Organisation from birth to 2 years and calculation of new percentiles and LMS values author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Archivos argentinos de pediatría

Print version ISSN 0325-0075On-line version ISSN 1668-3501


DONATO, Hugo et al. Recombinant erythropoietin as treatment for hyporegenerative anemia following hemolytic disease of the newborn. Arch. argent. pediatr. [online]. 2009, vol.107, n.2, pp.119-125. ISSN 0325-0075.

Introduction. The aim of the study is to report results of erythropoietin treatment for late hyporegenerative anemia in the hemolytic disease of the newborn (HDN). Reports previously published concern only a few cases, with controversial results. Methods. Case series report concerning 50 neonates with HDN due to Rh, ABO or KpA antigens, aged more than 7 days. Erythropoietin treatment started when hematocrit dropped to levels requiring transfusion, with an inappropriate reticulocyte response (Reticulocyte Production Index <1). Results. At start of treatment mean age was 24.3 ± 12.0 days (range 8-65 days), hematocrit 24.1 ± 2.8% (range 18-30%), and Reticulocyte Production Index 0.34 ± 0.25 (range 0.05-0.98). Hematocrit and Reticulocyte Production Index showed significant increases after 7 and 14 days of treatment (p <0.001). No difference was observed either between infants with Rh-HDN and ABO-HDN or between Rh-HDN patients with or without intrauterine transfusions. Seven infants (14%) required one packed RBC transfusion during erythropoietin therapy, 2 of them within 72 hours from starting treatment. The percentage of transfused infants showed no difference either between ABO-HDN and Rh-HDN or between Rh-HDN with and without intrauterine transfusions. Moderate, short-lasting neutropenia, not associated to infections, was observed in 11 patients. No other adverse effect was observed. Conclusions. The administration of erythropoietin appears to be a safe and useful therapy. Its efficacy should be confirmed by randomized studies.

Keywords : Hemolytic disease of the newborn; Rh hemolytic disease; ABO hemolytic disease; Anemia; Neonate.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License